Investors

Investors image

News

Jun.12, 2026 Notice
Shionogi Announces Investment in Dioseve, Inc. through Its CVC Activities
Jun.05, 2026 Release
ENDEAVORRIDE® Digital Therapeutic App for Adjunctive Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder (ADHD) Launched in Japan
Jun.01, 2026 Notice
(Corrections) Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure
Jun.01, 2026 Release
Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure
May.29, 2026 Release
Notice Regarding Approval of Naldemedine for Opioid-Induced Constipation in China
  • Latest IR Information

    ・Financial Results / Supplement

    　- Presentation material

    　- Transcript

    more
  • IR Library

    ・Financial Results / Supplement

    ・Presentation materials

    ・Annual Report / Integrated Report / EHS Report

    ・Corporate Governance Report

    ・Pipeline

    ・Fact Book

    more
  • Management Policy

    ・Philosophy

    ・Business Plan

    ・Corporate Governance

    ・Disclosure Policy

    ・Business Risks

    more
  • Shareholder Information

    ・Information on Shares

    ・General Meeting of Shareholders

    ・Analyst Coverage

    ・Bonds & Ratings

    more
  • Individual Investors

    ・Pharmaceutical Business

    ・Shionogi's Strength

    ・Business Strategy

    ・Business Activities, etc.

     

    more
  • Sustainability

    View the Shionogi's approach to sustainable growth

    more
  • Financial Highlights

    Financial highlights for the last five years

    more
  • IR Calendar

    The schedule and results of IR events in each fiscal year

     

    more